JNJ.DE Johnson & Johnson
Company Analysis
Latest News
🟢 Johnson & Johnson is trading 3.36% up — no clear catalyst identified
Johnson & Johnson is trading 3.36% higher at €235.00, with no clear catalyst identified. - The company announced rheumatology presentations and clinical data...
🟢 Johnson & Johnson is trading 3.09% up today as investors rotate from technology
Johnson & Johnson is trading at €231.70, up 3.09%, with the healthcare-sector rally supporting the move as investors rotate away from technology. - XLV is up...
Johnson & Johnson Eyes $100B Sales, Stock Slips on MedTech Miss
Johnson & Johnson raised its 2026 sales guidance to exceed $100 billion for the first time. The company's third-quarter revenue and earnings surpassed analyst...
Johnson & Johnson Beat on Earnings and Raised Guidance — So Why Are Investors Running for the Exits?
Shares plunged as much as 5.7% on October 13 after Johnson & Johnson's quarterly results revealed a widening crack in its medical-device business, erasing...
🔴 Johnson & Johnson is trading 5.6% down after MedTech sales missed estimates
Johnson & Johnson is trading at €222.15 (-5.61%) after its October 13 MedTech sales missed analysts’ estimate. - MedTech sales grew 2.5% to $8.6 billion,...
🔴 Johnson & Johnson is trading 3.1% down
Johnson & Johnson is trading 3.1% down at €228.05, with no confirmed cause for the decline. - On October 13, the company reported third-quarter adjusted EPS...
🔴 Johnson & Johnson is trading 3.03% down today amid rising oil prices and Treasury yields
Johnson & Johnson is trading at €225.75, down 3.03%, amid broader market pressure. - No clear company-specific catalyst surfaced; the decline appears...
🟢 Johnson & Johnson is trading 3.17% up — no clear catalyst identified
Johnson & Johnson is trading 3.17% up at €232.80, with no clearly reported company-specific catalyst identified for the October 7 move. - A pre-market report...
Johnson & Johnson Reports 70% Skin Response With ICOTYDE at Two Years
Johnson & Johnson announced long-term results from the Phase 3 ICONIC-TOTALa study of ICOTYDE® (icotrokinra), an oral treatment for plaque psoriasis. Presented...
Johnson & Johnson Reports 50% Five-Year Progression-Free Survival With CARVYKTI
Johnson & Johnson announced long-term follow-up results from the Phase 2 CARTITUDE-2 study of CARVYKTI. Half of the patients with early-line relapsed or...
Johnson & Johnson Reports Myeloma Combo May Bring Near-Normal Life Expectancy
Johnson & Johnson announced new analyses from its Phase 3 MajesTEC-3 study of TECVAYLI and DARZALEX FASPRO in patients with relapsed or refractory multiple...
Johnson & Johnson Gains European Approval for New Psoriasis Drug ICOTYDE
Johnson & Johnson received marketing authorization from the European Commission for ICOTYDE (icotrokinra). ICOTYDE treats adults and adolescents with...
Johnson & Johnson's CAPLYTA Shows Positive Phase 3 Results in Treating Bipolar Mania
Johnson & Johnson announced positive topline results from a pivotal Phase 3 trial for its drug CAPLYTA® (lumateperone). The trial evaluated CAPLYTA in treating...
J&J targets double-digit growth, defying $4.5 billion patent cliff
Johnson & Johnson CFO Joe Wolk expects the company to surpass its long-term growth target of 5% to 7%. Wolk projected double-digit enterprise growth by the end...
J&J’s Tecvayli Gains EU Backing for Second-Line Multiple Myeloma
Johnson & Johnson received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for Tecvayli (teclistamab). The...
Johnson & Johnson Sells Laminar Heart Device, Following Halted Clinical Trial
Johnson & Johnson is selling its Laminar left atrial appendage (LAA) closure device assets to Jaguar LAA. Jaguar LAA is a new entity formed by investment firm...
Johnson & Johnson's Depression Drug Fails Mid-Stage Study
Johnson & Johnson's experimental drug, JNJ-5120/PIPE-307, failed its primary goal in a Phase 2 clinical trial for major depressive disorder (MDD). The...
J&J’s Rybrevant Extends Lung Cancer Survival to Record 34.3 Months
Johnson & Johnson released final overall survival data from the Phase 3 PAPILLON study for its cancer treatment, Rybrevant. The trial evaluated Rybrevant...
Apollo's $20 Billion Bid for J&J's Hip-and-Knee Business: Smart Portfolio Surgery or a Discount Sale?
Reports emerged Friday that Apollo Global Management is in advanced talks to buy Johnson & Johnson's orthopedics division — the world's largest maker of hip...
Apollo nears $20 billion deal for J&J orthopedics unit
Apollo Global Management is in discussions to acquire Johnson & Johnson’s DePuy Synthes orthopedics business. The potential deal is valued at nearly $20...